Oncology pharmacotherapy: Once-daily aminoglycosides in patients with neutropenic fever

Cancer Control

Volumn 9, Issue 5, 2002, Pages 426-431

  Aiken, Stephen K ^a   Wetzstein, Gene A ^b  

^a Mission St Joseph's Health System   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; GENTAMICIN; NETILMICIN; TOBRAMYCIN; ANTIINFECTIVE AGENT; LACTAM;

ANTIBIOTIC THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; FEBRILE NEUTROPENIA; HUMAN; NEPHROTOXICITY; OTOTOXICITY; REVIEW; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG COMBINATION; EAR DISEASE; FEVER; GRAM NEGATIVE INFECTION; KIDNEY DISEASE; METHODOLOGY; NEUTROPENIA; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG THERAPY, COMBINATION; EAR DISEASES; FEVER; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; KIDNEY DISEASES; LACTAMS; NETILMICIN; NEUTROPENIA; TREATMENT OUTCOME;

EID: 0036716612     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480200900509     Document Type: Review

References (47)

1. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med. 1993;119(7 pt 1):584-593.
2. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-751.
3. Preston SL, Briceland LL. Single daily dosing of aminoglycosides. Pharmacotherapy. 1995;15:297-316.
4. Rice DAK. Once daily aminoglycosides. Clin Trends Pharm Pract. 1996;10:9-15.
5. Freeman CD, Nicolau DP, Belliveau PP, et al. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Amtimicrob Chemother. 1997;39:677-686.
6. McDonald PJ, Wetherall BL, Pruul H. Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes. Rev Infect Dis. 1981;3:38-44.
7. Gibson J, Johnson L, Snowdon L, et al. Single daily ceftriaxone and tobramycin in the empirical management of febrile neutropenic patients: a randomised trial. Int J Hematol. 1993;58:63-72.
8. Rozdzinski E, Kern W, Reichle A, et al. Once-daily versus thrice-daily dosing of netilmicin in combination with beta-lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother. 1993;31:585-598.
9. Hansen M, Achen F, Carstensen C, et al. Once- versus thrice-daily dosing of netilmicin in febrile immunocompromised patients: a randomized, controlled study of efficacy and safety. Journal of Drug Development. 1988;1(suppl 3):119-124.
10. Bakri FE, Pallett A, Smith AG, et al. Once-daily versus multiple-daily gentamicin in empirical antibiotic therapy of febrile neutropenia following intensive chemotherapy. J Antimicrob Chemother. 2000;45:383-386.
11. Charnas R, Luthi AR, Ruch W. Once daily ceftriaxone plus amikacin vs three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Pediatr Infect Dis J. 1997;16:346-353.
12. MacArthur RD, Lolans V, Zar FA, et al. Biphasic, concentration-dependent and rate-limited, concentration-independent bacterial killing by an aminoglycoside antibiotic. J Infect Dis. 1984;150:778-779.
13. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis. 1984;149:443-448.
14. Dudley MN, Zinner SH. Single daily dosing of amikacin in an in vitro model. J Antimicrob Chemo. 1991;27(suppl C):15-19.
15. Begg EJ, Peddie BA, Chambers ST, et al. Comparison of gentamicin dosing regimens using an in-vitro model. J Antimicrob Chemother. 1992;29:427-433.
16. Blaser J, Stone BB, Groner MC, et al. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother. 1987;31:1054-1060.
17. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155:93-99.
18. Ericsson CD, Fischer RP, Rowlands BJ, et al. Prophylactic antibiotics in trauma: the hazards of underdosing. J Trauma. 1989;29:1356-1361.
19. Verpooten GA, Giuliano RA, Verbist L, et al. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther. 1989;45:22-27.
20. Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39:650-655.
21. Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis. 1997;24:796-809.
22. Bailey TC, Little JR, Littenberg B, et al. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis. 1997;24:786-795.
23. Ferriols-Lisart R, Alos-Alminana M. Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health Syst Pharm. 1996;53:1141-1150.
24. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med. 1996;124:717-725.
25. Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother. 1996;37:645-663.
26. Barza M, Ioanaidis JP, Cappelleri JC, et al. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ. 1996;312:338-345.
27. Blaser J, Konig C. Once-daily dosing of aminoglycosides. Eur J Clin Microbiol Infect Dis. 1995;14:1029-1038.
28. Galloe AM, Graudal N, Christensen HR, et al. Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol. 1995;48:39-43.
29. Brummett RE, Fox KE. Aminoglycoside-induced hearing loss in humans. Antimicrob Agents Chemother. 1989;33:797-800.
30. Kibbler CC, McWhinney PH, Warner P, et al. Ototoxicity associated with a once daily dose amikacin regimen in febrile neutropenic patients. J Antimicrob Chemother. 1992;29:463-464.
31. Tran Ba Huy P, Deffrennes D. Aminoglycoside ototoxicity: influence of dosage regimen on drug uptake and correlation between membrane binding and some clinical features. Acta Otolaryngol. 1988;105:511-515.
32. Warkentin D, Ippoliti C, Bruton J, et al. Toxicity of single daily dose gentamicin in stem cell transplantation. Bone Marrow Transplant. 1999;24:57-61.
33. Craig WA. Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man. J Antimicrob Chemother. 1993;31(suppl D):149-158.
34. Spivey JM. The postantibiotic effect. Clin Pharm. 1992;11:876-877.
35. Karlowsky JA, Zelenitsky SA, Zhanel GG. Aminoglycoside adaptive resistance. Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic model. Pharmacotherapy. 1997;17:549-555.
36. Lacy MK, Nicolau DP, Nightingale CH, et al. The pharmacodynamics of aminoglycosides. Clin Infect Dis. 1998;2723-27.
37. Craig WA. Once-daily versus multiple-daily dosing of aminoglycosides. J Chemother. 1995;7(suppl 2):47-52.
38. Daikos GL, Jackson GG, Lolans VT, et al. Adaptive resistance to aminoglycosides antibiotics from first-exposure down-regulation. J Infect Dis. 1990;162:414-420.
39. Daikos GL, Lolans VT, Jackson GG. First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. Antimicrob Agents Chemother. 1991;35:117-123.
40. Rapoport BL, Sussmann O, Herrera MV, et al. Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs standard in-patient care. Chemotherapy. 1999;45:466-476.
41. Nicolau DP, Wu AH, Finocchiaro S, et al. Once-daily aminoglycoside dosing: impact on requests and costs for therapeutic drug monitoring. Ther Drug Monit. 1996;18:263-266.
42. Cornely OA, Bethe U, Salzberger B, et al. Randomized controlled monocentric comparison of once daily ceftriaxone with tobramycin and cefotaxime three times daily with tobramycin in neutropenic fever. Ann Hematol. 2001;80:103-108.
43. Gilbert C, Meisenberg B, Vredenburgh J, et al. Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. J Clin Oncol. 1994;12:1005-1011.
44. Cooke RP, Grace RJ, Gover PA. Audit of once-daily dosing gentamicin therapy in neutropenic fever. Int J Clin Pract. 1997;51:229-231.
45. Hatala R, Dinh TT, Cook DJ. Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review. Clin Infect Dis. 1997;24:810-815.
46. Nicolau D, Quintiliani R, Nightingale CH, et al. Once-daily aminoglycosides. Conn Med. 1992;56:561-563.
47. Van der Auwera P, Meunier F, Ibrahim S, et al. Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection. Antimicrob Agent Chemother. 1991;35:640-647.